The anticipated size of the Steroid-Free Nasal Sprays Market in 2022 was US$ 8,141.9 million and is estimated to be US$ 8,577.5 million in 2023. Market for the global steroid-free nasal sprays market is important with the rise in demand increased number of regulatory approvals have been observed in the steroid-free nasal sprays market which is propelling the launch of innovative products. Manufacturers in the market are mainly focusing on getting regulatory approvals to improve sales in the market. Future Market Insights has mentioned in its reports that the steroid-free nasal sprays market will expand at a CAGR of 6.4% between 2023 and 2033, totaling around US$ 15,908.1 million by 2033.
The global steroid-free nasal sprays market was valued at US$ 7.7 billion in 2021 and is expected to reach US$ 14.9 Billion by 2032, with sales growing at a 6.3% CAGR over the assessment period.
Subsequent rise has been found in the prevalence of allergies and infections worldwide where among the most prevalent type of allergy is allergic rhinitis. Allergic rhinitis includes allergies and hay fever to stimulants such as plants, mold, dust, and animal dander. The prevalence of allergic rhinitis will spur the demand for steroid-free nasal sprays in the global market.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | US$ 8,141.9 million |
| Projected Forecast Value (2023) | US$ 8,577.5 million |
| Projected Forecast Value (2033) | US$ 15,908.1 million |
| Growth rate | 6.4% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Global steroid-free nasal sprays market grew at a CAGR of 4.4% between 2017 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.4% between 2023 and 2033.
Nasal routes of delivery have been in practice for decades and are widely renowned routes for topical treatment of local diseases in the nasal cavity such as allergic and non-allergic rhinitis and nasal congestion.
Advantages of nasal, mucosal, and sublingual spray delivery are well known and offer non-invasiveness (compared to injections) and easy accessibility for administration. In addition to this, greater mucosal surface area, use of a relatively large, highly vascularized, high systemic bioavailability for some drugs, avoidance of hepatic first-pass metabolism, and the potential for rapid onset of drug action can be achieved.
Easy application without the necessity of trained personnel is improving patient compliance as compared parenteral route.
Key players in the steroid-free nasal sprays market are actively focused on research and development to launch nasal sprays that can also be used as vaccines. Intranasal vaccination also provides a promising non-invasive and gentle alternative.
For instance, in March 2021, the University of Oxford began with the phase-1 clinical trial of a nasal spray formulation of its AstraZeneca-partnered COVID-19 vaccine.
Considering this, FMI expects the global steroid-free nasal sprays market to grow at a CAGR of 6.3% through 2032.
Growth and Innovation in the Pharmaceutical Industry
Growth and innovations in the pharmaceutical industry help in the manufacturing of steroid nasal-free spray products that owes to a colossal pool of health-conscious consumers creating a nasal spray market opportunity for the market. Growth of the steroid nasal-free spray market size is anticipated to be driven by the high potentiality in untapped, emerging markets, because of the presence of improved healthcare infrastructure, with the rise in unmet healthcare needs and a rise in the prevalence of chronic respiratory disease. Healthcare industry in emerging economies is considered to be developing at a compelling rate, which owes to a rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructural, and the development of the medical tourism industry in emerging countries.
Principal Consultant
Availability of Preservative-free Formulations or Dry Powders Offering Opportunities to its Consumers
Recent developments are addressing the medical needs for depression, the CNS comprises various areas, some of which are with high unmet medical needs which includes schizophrenia, Alzheimer’s disease, Parkinson’s disease, insomnia, ADH, bipolar, and anxiety disorders, where non-invasive nasal delivery could prove to be beneficial.
Nasal sprays that contain preservative-free formulations or dry powders offer opportunities to avoid the use of preservatives and their potential complications. Typical preservatives such as benzalkonium chloride, parabens, and ethylene diamine tetra-acetic acid (EDTA) have been reported to cause damage to the nasal mucosa when used in chronic therapies and have side effects such as hindrance of the ciliary clearing functions within the nasal cavity.
Higher preference for preservative-free formulations to avoid these side effects which will create opportunities for the steroid-free nasal sprays market.
Prolonged Usage of the Nasal Spray Effect the Receptors on the Blood Vessels in the Nose
Nasal sprays provide a very safe and effective treatment for allergic rhinitis when taken for a short length of time as it is only recommended for a maximum of three days in a row.
Prolonged usage of the nasal spray may cause the receptors on the blood vessels in the nose to be downregulated which means when the number of receptors decreases, a rebound response of nasal inflammation, known as rhinitis medicamentosa, may develop when the user quits taking the drug. Long-term usage of certain sprays might harm tissue, resulting in infection and pain.
Patients who use a nasal spray regularly develop the habit of overusing the drug which causes different complications, and it is a setback for the growth of the steroid-free nasal spray market.
Several products have been recalled from the steroid-free nasal spray market due to the side effect observed, thus, these factors are expected to limit sales in the market over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Consumers are Preferring Steroid-free Nasal Sprays for Allergies
North America holds a major portion of the market share at 35.4% whereas the United States holds a dominant part with a market share of 32.8%
United States accounted for 92% of the North American steroid-free nasal sprays market in 2021 and is expected to continue its dominance over the forecast period. Key players in the USA are focusing to bring differentiated products to address unmet needs regarding allergic rhinitis.
Expansion for Therapeutic Applications for Steroid-free Nasal Sprays
Europe is said to hold a market share of 29.4% whereas Germany holds a market share of 7.1% and the United Kingdom is said to grow in the market at a CAGR of 6.0%
Provision of intranasal administration in various useful options for the local and systemic delivery of diversified therapeutic agents for the treatment of allergies, respiratory diseases, etc.
Rising Preference for Steroid-free Allergy Nasal Sprays in Japan Will Fuel Growth
Japan is an emerging market for steroid-free nasal sprays and accounted for a market share of 5.3% in the East Asia steroid-free nasal sprays market, owing to the increasing prevalence of allergic rhinitis in the country.
According to the Japanese Society of Allergology, the prevalence of perennial allergic rhinitis is common among young people and there is a significant rise in the cases of allergic rhinitis.
Players in the country are promoting their products through online channels. For instance, in January 2021, Avantor, Inc, launched its Japanese e-commerce website, jp.vwr.com to better serve customers locally with access to the company's broad portfolio of products and services, and related information.
Expansion in the Pharmaceutical Sector in India Will Boost Sales of Steroid-free Nasal Sprays
India accounted for more than 45% of the South Asia market growing at a CAGR of 7.2%. Manufacturers in India are launching generic versions that are less expensive to improve sales. increase the reach of the products to their customers.
Rise in Allergic-Rhinitis acts as a Serious Health Problem
Steroid-free nasal spray market in China is said to grow at a CAGR of 7.0%
Allergic rhinitis (AR) acts a serious problem for public health and medical concern because it acts as a risk factor that causes several disorders and diseases, mainly in children thus, rising, and significantly impacting the Chinese population.
Demand for Nasal Antihistamine Sprays Will Gain Momentum
Sales of nasal antihistamine sprays will increase at a market share of 34.60% over the assessment period, as these sprays are the most widely used due to their clinical benefits and the least side effects.
Nasal antihistamine sprays are used to treat seasonal allergies, allowing a person to apply the medicine directly to the nose and help in treating the allergy symptoms at the source and may cause fewer side effects than pills.
Individuals are Preferring Aqueous Steroid-free Nasal Sprays for Allergies
Aqueous by-formulation segment dominated the steroid-free nasal sprays market with a 55.05% value share as they account for the highest market share because it provides rapid drug absorption into the mucous membrane as highly adopted by individuals as they are easier to use and widely available.
Sales of Steroid-free Nasal Sprays Through Institutional Channels Remain High
Sales in the institutional segment are expected to increase at a 6% CAGR over the assessment period where the segment is accounted for 57.7% of the total market share. Increasing need for steroid-free nasal sprays for respiratory allergies, and frequent prescriptions by doctors are propelling sales in hospitals and specialty clinic settings.
Some of the prominent players in the global market are-
Some of the important developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.4% from 2023 to 2033 |
| Market value in 2023 | US$ 8,577.5 million |
| Market value in 2033 | US$ 15,908.1 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customisation Scope | Available on Request |
From 2018 to 2022, sales increased at a CAGR of 4.4%.
The market is expected to continue to evolve at a 6.4% CAGR through 2033.
The market is expected to climb to US$ 15,908.1 million by 2033.
The market is expected to be valued at US$ 8,577.5 million in 2023.
North America accounts for a significant part of the market, encompassing 35.4%.
With a market share of 32.8%, the United States dominates.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Antihistamine
5.3.2. Decongestant
5.3.3. Anticholinergic
5.3.4. Cromolyn Sodium
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Formulation
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Formulation, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Formulation, 2023 to 2033
6.3.1. Aqueous
6.3.2. Suspension
6.3.3. Nonaqueous-Based Solution
6.3.4. Hydroalcoholic
6.3.5. Emulsions
6.3.6. Dry Powder/Micro Particles
6.4. Y-o-Y Growth Trend Analysis By Formulation, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Formulation, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Institutional Sales
7.3.1.1. Hospitals
7.3.1.2. Specialty Clinics
7.3.1.3. Community Clinics
7.3.1.4. Public Health Agencies
7.3.1.5. Others
7.3.2. Retail Sales
7.3.2.1. Retail Pharmacy
7.3.2.2. Drug Stores
7.3.2.3. Mail Order Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Product
9.2.3. By Formulation
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By Formulation
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product
10.2.3. By Formulation
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Formulation
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Product
11.2.3. By Formulation
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Formulation
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Product
12.2.3. By Formulation
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Formulation
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Product
13.2.3. By Formulation
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Formulation
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Product
14.2.3. By Formulation
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Formulation
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Product
15.2.3. By Formulation
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Formulation
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product
16.1.2.2. By Formulation
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product
16.2.2.2. By Formulation
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product
16.3.2.2. By Formulation
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product
16.4.2.2. By Formulation
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product
16.5.2.2. By Formulation
16.5.2.3. By Distribution Channel
16.6. U.K.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product
16.6.2.2. By Formulation
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product
16.7.2.2. By Formulation
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product
16.8.2.2. By Formulation
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product
16.9.2.2. By Formulation
16.9.2.3. By Distribution Channel
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product
16.10.2.2. By Formulation
16.10.2.3. By Distribution Channel
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product
16.11.2.2. By Formulation
16.11.2.3. By Distribution Channel
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product
16.12.2.2. By Formulation
16.12.2.3. By Distribution Channel
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product
16.13.2.2. By Formulation
16.13.2.3. By Distribution Channel
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product
16.14.2.2. By Formulation
16.14.2.3. By Distribution Channel
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product
16.15.2.2. By Formulation
16.15.2.3. By Distribution Channel
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product
16.16.2.2. By Formulation
16.16.2.3. By Distribution Channel
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product
16.17.2.2. By Formulation
16.17.2.3. By Distribution Channel
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product
16.18.2.2. By Formulation
16.18.2.3. By Distribution Channel
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Product
16.19.2.2. By Formulation
16.19.2.3. By Distribution Channel
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Product
16.20.2.2. By Formulation
16.20.2.3. By Distribution Channel
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Product
16.21.2.2. By Formulation
16.21.2.3. By Distribution Channel
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Product
16.22.2.2. By Formulation
16.22.2.3. By Distribution Channel
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Product
16.23.2.2. By Formulation
16.23.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product
17.3.3. By Formulation
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Janssen Pharmaceutical, Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Astra Zeneca Plc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Cipla Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Glenmark Pharmaceuticals
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Glaxosmithkline Plc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Novartis International AG
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Procter & Gamble
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Sanofi S.A. (Sanofi-aventis LLC.)
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Boehringer Ingelheim GmbH
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. AdvaCare Pharma
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
18.1.11. Bayer AG (Bayer Consumer Health
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.11.5.2. Product Strategy
18.1.11.5.3. Channel Strategy
18.1.12. Covis Pharma S.a.r.l.
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.12.5.2. Product Strategy
18.1.12.5.3. Channel Strategy
18.1.13. Nipro Corporation (NIPRO JMI Pharma Ltd.)
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
18.1.13.5.2. Product Strategy
18.1.13.5.3. Channel Strategy
18.1.14. Viatris Inc. (Meda Pharmaceuticals Inc.)
18.1.14.1. Overview
18.1.14.2. Product Portfolio
18.1.14.3. Profitability by Market Segments
18.1.14.4. Sales Footprint
18.1.14.5. Strategy Overview
18.1.14.5.1. Marketing Strategy
18.1.14.5.2. Product Strategy
18.1.14.5.3. Channel Strategy
18.1.15. Perrigo Company plc
18.1.15.1. Overview
18.1.15.2. Product Portfolio
18.1.15.3. Profitability by Market Segments
18.1.15.4. Sales Footprint
18.1.15.5. Strategy Overview
18.1.15.5.1. Marketing Strategy
18.1.15.5.2. Product Strategy
18.1.15.5.3. Channel Strategy
18.1.16. AptarGroup, Inc.
18.1.16.1. Overview
18.1.16.2. Product Portfolio
18.1.16.3. Profitability by Market Segments
18.1.16.4. Sales Footprint
18.1.16.5. Strategy Overview
18.1.16.5.1. Marketing Strategy
18.1.16.5.2. Product Strategy
18.1.16.5.3. Channel Strategy
18.1.17. Berry Global, Inc.
18.1.17.1. Overview
18.1.17.2. Product Portfolio
18.1.17.3. Profitability by Market Segments
18.1.17.4. Sales Footprint
18.1.17.5. Strategy Overview
18.1.17.5.1. Marketing Strategy
18.1.17.5.2. Product Strategy
18.1.17.5.3. Channel Strategy
18.1.18. URSATEC GmbH
18.1.18.1. Overview
18.1.18.2. Product Portfolio
18.1.18.3. Profitability by Market Segments
18.1.18.4. Sales Footprint
18.1.18.5. Strategy Overview
18.1.18.5.1. Marketing Strategy
18.1.18.5.2. Product Strategy
18.1.18.5.3. Channel Strategy
18.1.19. Gerresheimer AG
18.1.19.1. Overview
18.1.19.2. Product Portfolio
18.1.19.3. Profitability by Market Segments
18.1.19.4. Sales Footprint
18.1.19.5. Strategy Overview
18.1.19.5.1. Marketing Strategy
18.1.19.5.2. Product Strategy
18.1.19.5.3. Channel Strategy
18.1.20. Avantor, VWR International, LLC
18.1.20.1. Overview
18.1.20.2. Product Portfolio
18.1.20.3. Profitability by Market Segments
18.1.20.4. Sales Footprint
18.1.20.5. Strategy Overview
18.1.20.5.1. Marketing Strategy
18.1.20.5.2. Product Strategy
18.1.20.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Steroid-Free Nasal Sprays Market
